Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist - Merck
- Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist Merck
- Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal CNBC
- Live news: Merck strikes $2bn deal with Chinese biotech to develop oral weight-loss drug Financial Times
- Merck in Pact for Chinese Obesity Drug in Nearly $2 Billion Deal Bloomberg
- Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug Fierce Biotech